Hildebrandt Anke, Zintl Annetta, Montero Estrella, Hunfeld Klaus-Peter, Gray Jeremy
St. Vincenz Hospital Datteln, Department of Internal Medicine I, 45711 Datteln, Germany.
Institute of Medical Microbiology, University Hospital Münster, 48149 Münster, Germany.
Pathogens. 2021 Sep 9;10(9):1165. doi: 10.3390/pathogens10091165.
Babesiosis is attracting increasing attention as a worldwide emerging zoonosis. The first case of human babesiosis in Europe was described in the late 1950s and since then more than 60 cases have been reported in Europe. While the disease is relatively rare in Europe, it is significant because the majority of cases present as life-threatening fulminant infections, mainly in immunocompromised patients. Although appearing clinically similar to human babesiosis elsewhere, particularly in the USA, most European forms of the disease are distinct entities, especially concerning epidemiology, human susceptibility to infection and clinical management. This paper describes the history of the disease and reviews all published cases that have occurred in Europe with regard to the identity and genetic characteristics of the etiological agents, pathogenesis, aspects of epidemiology including the eco-epidemiology of the vectors, the clinical courses of infection, diagnostic tools and clinical management and treatment.
巴贝斯虫病作为一种全球范围内新出现的人畜共患病正日益受到关注。欧洲首例人类巴贝斯虫病病例于20世纪50年代末被描述,自那时起欧洲已报告了60多例病例。虽然该病在欧洲相对罕见,但它很重要,因为大多数病例表现为危及生命的暴发性感染,主要发生在免疫功能低下的患者中。尽管在临床上该病与其他地方(特别是美国)的人类巴贝斯虫病相似,但欧洲的大多数病例类型是不同的实体,尤其是在流行病学、人类对感染的易感性以及临床管理方面。本文描述了该病的历史,并回顾了欧洲已发表的所有病例,内容涉及病原体的身份和遗传特征、发病机制、流行病学方面(包括媒介的生态流行病学)、感染的临床病程、诊断工具以及临床管理和治疗。